EyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Overweight Rating from Cantor Fitzgerald

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $31.00 target price on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 207.23% from the company’s current […]

Related Keywords

China ,United Kingdom ,United States , ,Eyepoint Pharmaceuticals Inc ,News Ratings For Eyepoint Pharmaceuticals Daily ,Citigroup Inc ,Cantor Fitzgerald ,Eyepoint Pharmaceuticals ,Insider Activity At Eyepoint Pharmaceuticals ,Analyst Recommendations For Eyepoint Pharmaceuticals ,Tower Research Capital ,Lazard Asset Management ,Barclays Plc ,Institutional Investors Weigh In On Eyepoint Pharmaceuticals ,Eyepoint Pharmaceuticals Price Performance ,Cubist Systematic Strategies ,Get Free Report ,Chardan Capital ,Point Pharmaceuticals ,Research Capital ,Asset Management ,Systematic Strategies ,Eyepoint Pharmaceuticals Daily ,Nasdaq Eypt ,Eypt ,Medical ,Reiterated Rating ,